These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 2439426)

  • 21. Valuable predictive features of relapse of Graves' disease after antithyroid drug treatment.
    Liu X; Shi B; Li H
    Ann Endocrinol (Paris); 2015 Dec; 76(6):679-83. PubMed ID: 26514949
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Concentration of TSH-receptor antibodies (TBII) in the sera of patients with immunogenic hyperthyroidism (Graves' disease) receiving antithyroid medication.
    Budihna N; Pavlin K; Porenta M
    Radiobiol Radiother (Berl); 1987; 28(1):101-6. PubMed ID: 2438715
    [No Abstract]   [Full Text] [Related]  

  • 23. Relapse of Graves' disease after successful outcome of antithyroid drug therapy: results of a prospective randomized study on the use of levothyroxine.
    Hoermann R; Quadbeck B; Roggenbuck U; Szabolcs I; Pfeilschifter J; Meng W; Reschke K; Hackenberg K; Dettmann J; Prehn B; Hirche H; Mann K;
    Thyroid; 2002 Dec; 12(12):1119-28. PubMed ID: 12593726
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Determination of thyroid stimulating immunoglobulins (TSI) during the course of Graves' disease. A reliable indicator for remission and persistence of this disease?
    Schleusener H; Finke R; Kotulla P; Wenzel KW; Meinhold H; Roedler HD
    J Endocrinol Invest; 1978 Apr; 1(2):155-61. PubMed ID: 90689
    [No Abstract]   [Full Text] [Related]  

  • 25. Persistence of thyrotropin (TSH) receptor antibodies in children and adolescents with Graves' disease treated using antithyroid medication.
    Smith J; Brown RS
    Thyroid; 2007 Nov; 17(11):1103-7. PubMed ID: 17822376
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Response to TRH, serum thyroid hormone concentration, and serum markers of autoimmunity after antithyroid therapy in Graves' disease.
    Lamberg BA; Aro A; Saarinen P; Tötterman T; Mäkinen T
    J Endocrinol Invest; 1978 Jan; 1(1):9-16. PubMed ID: 90688
    [No Abstract]   [Full Text] [Related]  

  • 27. Clinical applications of assays for thyrotropin-receptor antibodies in Graves' disease.
    Ginsberg J; von Westarp C
    CMAJ; 1986 May; 134(10):1141-7. PubMed ID: 2421862
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of methimazole with or without exogenous L-thyroxine on serum concentrations of thyrotropin (TSH) receptor antibodies in patients with Graves' disease.
    Rittmaster RS; Zwicker H; Abbott EC; Douglas R; Givner ML; Gupta MK; Lehmann L; Reddy S; Salisbury SR; Shlossberg AH; Tan MH; York SE
    J Clin Endocrinol Metab; 1996 Sep; 81(9):3283-8. PubMed ID: 8784084
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Are pituitary and thyroid function tests useful for the monitoring of antithyroid drug treatment and the post therapeutic control of Graves' disease?
    Jaffiol C; Baldet L; Castelnau P; Papachristou C; Lapinski H; Rouaud R
    Horm Res; 1987; 26(1-4):137-45. PubMed ID: 2439427
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hypothyroidism during antithyroid drug treatment with methimazole is a favorable prognostic indicator in patients with Graves' disease.
    Choo YK; Yoo WS; Kim DW; Chung HK
    Thyroid; 2010 Sep; 20(9):949-54. PubMed ID: 20629556
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Changes in serum thyroglobulin and thyroid autoantibodies in patients with Graves' disease treated with antithyroid drug and their relationship to relapse.
    Gong ST; Chao IM
    J Formos Med Assoc; 1991 Dec; 90(12):1155-62. PubMed ID: 1724781
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epitopes for thyroid-stimulating antibodies in Graves' sera: a possible link of heterogeneity to differences in response to antithyroid drug treatment.
    Kim WB; Cho BY; Park HY; Lee HK; Kohn LD; Tahara K; Koh CS
    J Clin Endocrinol Metab; 1996 May; 81(5):1758-67. PubMed ID: 8626830
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Two Graves' disease patients who spontaneously developed hypothyroidism after antithyroid drug treatment: characteristics of epitopes for thyrotropin receptor antibodies.
    Chung HK; Kim WB; Park DJ; Kohn LD; Tahara K; Cho BY
    Thyroid; 1999 Apr; 9(4):393-9. PubMed ID: 10319947
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Treatment of Graves' disease--antithyroid drug therapy].
    Onaya T
    Nihon Rinsho; 1999 Aug; 57(8):1846-50. PubMed ID: 10483263
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Change of circulating thyroid autoantibody titers in Graves' hyperthyroidism after antithyroid drugs therapy.
    Lin HD; Tai FT; Chen HD; Lee SP; Chang FY; Wang GG; Tang KT; Lee JK
    Zhonghua Yi Xue Za Zhi (Taipei); 1991 Feb; 47(2):86-90. PubMed ID: 1705860
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Changes in thyrotropin binding inhibiting immunoglobulins (TBII) in sera of patients with Graves' disease at the time of relapse or exacerbation.
    Uchimura H; Akimoto N; Mitsuhashi T; Kubota K; Kuzuya N; Imai Y; Ikeda H; Matsuzaki F; Kumagai LF
    J Endocrinol Invest; 1986 Feb; 9(1):37-42. PubMed ID: 2422245
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prospective multicentre study on the prediction of relapse after antithyroid drug treatment in patients with Graves' disease.
    Schleusener H; Schwander J; Fischer C; Holle R; Holl G; Badenhoop K; Hensen J; Finke R; Bogner U; Mayr WR
    Acta Endocrinol (Copenh); 1989 Jun; 120(6):689-701. PubMed ID: 2567102
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Do HLA-DR-typing and measurement of TSH-receptor antibodies help in the prediction of the clinical course of Graves' thyrotoxicosis after antithyroid drug treatment?
    Schleusener H; Schwander J; Holl G; Badenhoop K; Hensen J; Finke R; Schernthaner G; Mayr WR; Kotulla P
    Acta Endocrinol Suppl (Copenh); 1987; 281():318-24. PubMed ID: 2441554
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thyroid stimulating immunoglobulin in Graves' disease.
    Luttrell BM; Hales IB
    Aust N Z J Med; 1981 Jun; 11(3):293-8. PubMed ID: 6170289
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relapse of Graves' disease after medical therapy: predictive value of thyroidal technetium-99m uptake and serum thyroid stimulating hormone receptor antibody levels.
    Wilson R; McKillop JH; Pearson DW; Cuthbert GF; Thomson JA
    J Nucl Med; 1985 Sep; 26(9):1024-8. PubMed ID: 2863338
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.